Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naxitamab added to induction therapy for newly diagnosed high-risk neuroblastoma
2025-524140-35-00Phase 2Authorised
- Sponsor
- Fundació Sant Joan de Déu
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of naxitamab in neuroblastoma and ganglioneuroblastoma (GNB), sponsored by Fundació Sant Joan de Déu. Primary endpoint: Complete response rate at end of induction per 1993 INRC. Planned start May 2026; status: authorised.
02
Drugs
naxitamab
03
Conditions
neuroblastomaganglioneuroblastoma (GNB)
Beyond the preview
Go deeper on 2025-524140-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524140-35-00.